The latest learning and CPD content on mental health. Under ‘Other resources’ you will find all our other content related to mental health.
CPD and Learning
Diabetes: mental health considerations in adults Subscription
Pharmacists can contribute to the psychological and emotional wellbeing of people living with diabetes by helping to identify those who have mental wellbeing needs, optimising treatment and minimising risk factors.
Case-based learning: anxiety disordersSubscription
There are many types of anxiety disorders with varying levels of severity. Pharmacists should know the treatment options that are available and how to support patients.
This article considers how patients with schizophrenia should be managed when their condition or treatment changes.
Schizophrenia: recognition and management Subscription
Common medicines used to manage schizophrenia have many side effects that can cause significant morbidity. Regular monitoring and support can ensure patients improve outcomes.
Non-pharmacological interventions, such as maintaining good sleep hygiene and a healthy diet, can help improve, resolve or prevent depression.
Case-based learning: postnatal depressionSubscription
Appropriate early recognition and timely treatment of postnatal depression is essential if patients are to make a full recovery.
Postnatal depression: recognition and diagnosisSubscription
Pharmacists are likely to encounter patients affected by postnatal depression; therefore, the ability to identify signs of this under-recognised disorder is essential for appropriate and prompt referral for help and support.
A range of symptoms can indicate potential body dysmorphic disorder. Pharmacists should know how to have conversations about this condition and provide advice about the available treatments.
The most common alternative to pharmacological treatment offered to patients with depression and anxiety by the NHS is cognitive behavioural therapy, or ‘CBT’. This guide details how it works.
There is a lack of high-quality evidence supporting the use of cannabinoids in the treatment of mental disorders, the authors of a meta-analysis published in the Lancet Psychiatry have concluded.
One year since UK law changed to enable medical cannabis to be prescribed, researchers are exploring the drug’s potential for treating post-traumatic stress disorder, schizophrenia and attention deficit hyperactivity disorder.
Sertraline is unlikely to reduce depressive symptoms within six weeks, according to findings from a randomised controlled trial in The Lancet Psychiatry.
National Institute for Health and Care Excellence guidelines from 2005 may have inadvertently led to increased antidepressant prescribing in children aged under 18 years.
Antidepressants in the treatment of major depression: a changing landscape for clinical decision makingSubscription
With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed until late 2019, this article aims to examine the findings of the Cipriani et al. meta-analysis in the wider context of the management of depression in the UK.
From the perspective of their clinical and holistic role, and restriction of access to means, there are opportunities to involve pharmacy teams in suicide prevention. This article examines the published evidence-base and the success of ongoing programmes and initiatives in the United States and Canada to produce a set of recommendations for the benefit of UK practice on the opportunities community pharmacy teams have to raise awareness and help prevent suicide and self-harm.
Existing medicines for physical conditions such as diabetes and hypertension could be used to treat serious mental illness, concluded the authors of a recent study in JAMA Psychiatry.